Table 2 Effect of UMEC 31.25 and 62.5 mcg versus placebo on home trough FEV1
Time point | Placebo (N =143) | UMEC 31.25 mcg (N =139) | UMEC 62.5 mcg (N =139) | |
|---|---|---|---|---|
n | Weeks −2 and − 1 (BL) | 143 | 138 | 139 |
mean (SD) | 2.222 (0.805) | 2.304 (0.718) | 2.248 (0.662) | |
n | Weeks 1–4 | 141 | 135 | 138 |
LS mean change (SE) | −0.034 (0.023) | 0.029 (0.023) | 0.046 (0.023) | |
Difference vs placebo (95% CI) | 0.064 (0.000, 0.127) | 0.080 (0.017, 0.144) | ||
n | Weeks 5–8 | 139 | 128 | 135 |
LS mean change (SE) | − 0.046 (0.027) | 0.018 (0.027) | 0.063 (0.027) | |
Difference vs placebo (95% CI) | 0.064 (−0.011, 0.139) | 0.109 (0.034, 0.184) | ||
n | Weeks 9–12 | 135 | 130 | 132 |
LS mean change (SE) | −0.058 (0.027) | 0.045 (0.027) | 0.054 (0.027) | |
Difference vs placebo (95% CI) | 0.103 (0.028, 0.178) | 0.112 (0.037, 0.186) | ||
n | Weeks 13–16 | 128 | 124 | 125 |
LS mean change (SE) | −0.026 (0.028) | 0.052 (0.028) | 0.058 (0.028) | |
Difference vs placebo (95% CI) | 0.079 (0.000, 0.157) | 0.084 (0.006, 0.162) | ||
n | Weeks 17–20 | 126 | 123 | 124 |
LS mean change (SE) | −0.023 (0.029) | 0.039 (0.029) | 0.065 (0.029) | |
Difference vs placebo (95% CI) | 0.061 (−0.019, 0.142) | 0.087 (0.007, 0.167) | ||
n | Weeks 21–24 | 128 | 123 | 125 |
LS mean change (SE) | −0.038 (0.029) | 0.033 (0.030) | 0.081 (0.029) | |
Difference vs placebo (95% CI) | 0.071 (−0.011, 0.152) | 0.118 (0.037, 0.199) | ||
n | Weeks 1–24* | 142 | 137 | 138 |
LS mean change (SE) | −0.038 (0.024) | 0.036 (0.025) | 0.061 (0.024) | |
Difference vs placebo (95% CI) | 0.074 (0.006, 0.141) | 0.098 (0.031, 0.166) |